MGH/Harvard is recruiting adult males with Fragile X syndrome, 18 years or older, for a neuroimaging study. Participants will be compensated up to $350.
 
The aim of the study is to examine problems with a chemical messenger called glutamate in the brain in Fragile X syndrome, and how it impacts sensory, motor and cognitive abilities and implicated structural and functional connectivity.
 
Three visits at Massachusetts General Hospital are required:
  • Medical history and behavioral testing (approx. 1.5 hours)
  • PET-MRI (approx. 2 hours)
  • Magnetoencephalography (approx. 1 hour).

The study started on March 15, 2018, and ends by June 30, 2020. The IRB approval number is 2017P001039.

Travel/time subsidy: compensation up to $350 for participation.

If you are interested, please contact:

Maria Mody, PhD
maria@nmr.mgh.harvard.edu
(617) 726-6913

Our Most Recent Opportunities
If you arrived on this page through a MyFXResearch Portal search, you can close this window and return to your filtered results. Or start a new search here.

Survey: Cannabidiol (CBD) Use with Fragile X Syndrome

A Mount Sinai Genetic Counseling graduate student is conducting a research study to learn about possible benefits and side effects of CBD supplements when used to treat FXS symptoms. This information will be obtained by using an anonymous online parental and caregiver survey.  About the Survey Who can participate? Parents and caregivers caring for somebody with FXS who uses, or has used, CBD supplements may be eligible to participate. The parent or caregiver responding to the survey must be at least 18 years old. The individual with ...

Parents and Caregivers of Adults with Fragile X Syndrome Needed for a Survey

Kaylynn Shuleski, a master’s in genetic counseling candidate, is conducting a research study to explore the concerns and challenges caregivers may face when planning long-term supports and living arrangements for their adult children with Fragile X syndrome (FXS). This information will be valuable for current and future families when considering long-term supports, as well as for healthcare professionals, counselors, and policy makers.  About the Study Who can participate? Parents and caregivers of adults with full mutation ...